EAACI launched the new web-based and open access journal "Clinical and Translational Allergy" (CTA) in 2011. We believe that open access is the most important way to publish research in the future, and felt that EAACI needs to contribute to this development.
Impact Factor: 3.239
The journal accepts scientific papers and reviews in the allergy field, but both basic and clinical research. Some EAACI position papers will also be published in CTA. CTA will accept quality science, and will do its utmost to provide a very rapid and fair per-review process. More information about CTA can be found at www.ctajournal.com.
We invite you to submit your manuscript now at www.ctajournal.com/manuscript.
Discounts for publishing in CTAEAACI will be discounting the article processing charge for manuscripts published in CTA this year. There will be ten 50% discounts for JMAs and up to fifty 10% discounts for full EAACI members in addition to 10 full discretionary waivers for this year to cover invited and spontaneously submitted reviews. We hope that you will consider CTA for your original research and up-to-the minute reviews on topics of importance for clinicians and academics. Remember that CTA is your journal. The more you publish, the more the journal will succeed.
JMA-CTA CollaborationThe JMA Working Group is very pleased to announce a new collaboration with the Clinical and Translational Allergy (CTA) journal (www.ctajournal.com) - the JMA-CTA Collaboration. CTA welcomes the active involvement of the younger members of the Academy. Find out more here.
Last updated 22 November 2017